OEM News

MTF Biologics, Kolosis BIO Team Up to Strengthen DBX Brand

Expansion will enhance access to various demineralized bone matrix allografts.

Author Image

By: Michael Barbella

Managing Editor

Graphic: Business Wire.

MTF Biologics is growing its allograft solutions portfolio by expanding its strategic agreement with Kolosis BIO (Kolosis).

As part of this collaboration, Kolosis has grown the portfolio of MTF Biologics allograft solutions it represents and distributes to include DBX Mix and DBX Putty, providing various demineralized cortical bone matrix (DBM) solutions to surgeons and their patients.

“Kolosis has been a great collaborator for MTF Biologics for many years, and we share a dedication to delivering the highest-quality allograft solutions, while improving patient care and expanding the gift of donation,” said Brad Bailey, vice president and general manager of MTF Biologics’ Orthopedic Franchise. “We are excited to expand our partnership to include the DBX family of allograft tissues, which are used in many types of orthopedic surgery to help address a variety of challenges from spinal and joint fusion to non-healing fractures.”

Kolosis BIO provides biologic solutions, dedicated to commercializing cutting-edge technologies and delivering orthopedic products. As a pure-play biologics company, Kolosis exclusively partners with MTF Biologics to offer bone graft technologies such as Kore Fiber, a 100% demineralized cortical bone allograft; Prime HD, a pre-hydrated DBM; and now DBX. These allografts are backed by MTF Biologics’ proprietary aseptic processing methods that optimally preserve matrix structures and osteoinductive properties.

“We are honored to welcome the DBX brand into our expanding portfolio of bone graft solutions,” Kolosis BIO CEO Collin Begley stated. “With a 20-year legacy in the premium DBM category, DBX deserves the focus and dedication Kolosis will bring. We are excited to introduce it to new surgeons through our proven commercial team and sales channel.”

Kolosis is dedicated to driving innovation in the biologics field, expanding its product offerings, and pushing the boundaries of science to enhance patient outcomes.

MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients, and advancing science. It provides service, resources, and expertise to donors and their loved ones who give the gift of donation, people who depend on tissue and organ transplants, healthcare providers, and clinicians and scientists.

The International Institute for the Advancement of Medicine (IIAM), a Division of MTF Biologics, honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Statline, also a division of MTF Biologics, provides specialized screening, coordination, and communications services to organ transplant centers, organ, tissue, and eye procurement organizations, and the hospitals and patients that they serve. Its sister organization, Deutsches Institute for Zell-und Gewebeersatz – DIZG (The German Institute for Cell and Tissue Transplantation) expands its reach to patients globally.

Keep Up With Our Content. Subscribe To Orthopedic Design & Technology Newsletters